Iproniazid
From Wikipedia, the free encyclopedia
 |
This article does not cite any references or sources. (December 2007) Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. |
 |
|
|
Iproniazid
|
|
| Systematic (IUPAC) name | |
| N'-propan-2-ylpyridine-4-carbohydrazide | |
| Identifiers | |
| CAS number | |
| ATC code | N06 |
| PubChem | |
| Chemical data | |
| Formula | C9H13N3O |
| Mol. mass | 179.219 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
? |
| Routes | ? |
Iproniazid (iproniazid phosphate, marketed under the names Marsilid, Iprozid, Ipronid, Rivivol, Propilniazida) is a monoamine oxidase inhibitor (MAOI) that was developed as the first anti-depressant. It was originally intended to treat tuberculosis when it was discovered that patients given iproniazid became "inappropriately happy". Subsequently with further research iproniazid was marketed specifically for depression in 1958. It was later replaced by less hepatotoxic drugs, particularly isocarboxazid.
|
|||||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
